Heron Therapeutics, Inc. Q4 2025 Earnings Call Summary

Group 1 - The company is shifting to a high-growth strategy by expanding sales capacity in key geographies with favorable market access and established distributor relationships [1] - Oncology performance remains stable, with CINVANTI showing resilience against competition while the planned wind-down of SUSTOL continues [1] Group 2 - Permanent J-Codes for ZYNRELEF and APONVIE have improved reimbursement clarity, facilitating broader adoption in hospitals and ambulatory surgery centers [2] - Operational improvements, including the CrossLink IGNITE distributor incentive program and the introduction of the vial access needle (VAN), have significantly reduced hospital workflow friction [2] Group 3 - Acute Care performance reached a strategic inflection point in Q4 2025, with ZYNRELEF and APONVIE achieving year-over-year revenue growth of 48% and 97%, respectively [3] - The company completed a financing round that eliminated a long-standing capital structure overhang, allowing management to focus on commercial execution [3] - Full year 2026 guidance projects net product sales between $173 million and $183 million, with adjusted EBITDA expected to remain positive between $10 million and $20 million [3] - The company plans to increase commercial investments starting mid-2026, which may temporarily moderate EBITDA growth to prioritize long-term revenue acceleration and free cash flow in 2027 [3] - ZYNRELEF's prefilled syringe presentation is undergoing 12 months of stability testing, with a targeted FDA approval and launch window in mid- to late 2027 [3] - APONVIE adoption is expected to accelerate in the second half of 2026 due to its inclusion in the Fifth Consensus Guidelines for PONV management [3] - The NOPAIN Act is anticipated to serve as a significant tailwind as provider awareness of separate reimbursement for non-opioid treatments increases throughout 2026 [3]